What is SGMO's health score?

SANGAMO THERAPEUTICS, INC (SGMO) has a TradeApes health score of 38 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is SGMO's estimated fair value?

Based on our 5-year discounted cash flow model, SANGAMO THERAPEUTICS, INC's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is SGMO undervalued or overvalued?

Our model currently rates SGMO as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for SGMO... Refresh in a moment for the full analysis.

SANGAMO THERAPEUTICS, INC (SGMO)

Healthcare Inconclusive inconclusive weak

$0.22

Updated: 2026-06-04

TradeApes Score

Financial Strength

35 Weak

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

30 Weak

Risk

50 Mixed

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Excessive stock comp — SBC above 15% of revenue, wealth transfer to employees

Unlock Full Report →

1 free score card remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.